A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects

This study has been completed.
Sponsor:
Information provided by:
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00460954
First received: April 16, 2007
Last updated: August 13, 2008
Last verified: August 2008

April 16, 2007
August 13, 2008
June 2007
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00460954 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
An Open Label, Multiple-Dose Study ot Determine the Plasma Levodopa Profiles of Sinemet® CR (Carbidopa/Levodopa) at 4 Daily Dose Levels in Healthy Subjects

The purpose of this clinical research study is to determine if different dosage regimens of Sinemet® CR (Carbidopa/levodopa) are dose proportional

Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
Parkinson's Disease
Drug: Sinemet® controlled release (Carbidopa/levodopa)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
20
August 2007
Not Provided
  • Key inclusion and exclusion criteria for healthy volunteers will be used
  • Males and females aged 50-75
Both
50 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00460954
CN158-001
Not Provided
Not Provided
Bristol-Myers Squibb
Not Provided
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Bristol-Myers Squibb
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP